Poloxamer/Cyclodextrin/Chitosan-Based Thermoreversible Gel for Intranasal Delivery of Fexofenadine Hydrochloride

被引:69
作者
Cho, Hyun-Jong [1 ,2 ]
Balakrishnan, Prabagar [1 ,2 ]
Park, Eun-Kyoung [3 ]
Song, Ki-Won [3 ]
Hong, Soon-Sun [4 ]
Jang, Tae-Young [4 ]
Kim, Kyu-Sung [4 ]
Chung, Suk-Jae [1 ,2 ]
Shim, Chang-Koo [1 ,2 ]
Kim, Dae-Duk [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[3] Pusan Natl Univ, Sch Chem Engn, Pusan 609, South Korea
[4] Inha Univ, Sch Med, Inchon 400712, South Korea
关键词
nasal drug delivery; fexofenadine hydrochloride; thermoreversibility; poloxamer; 407; bioavailability; polymeric drug carrier; absorption enhancer; gels; HYDROXYPROPYL-BETA-CYCLODEXTRIN; NASAL DELIVERY; POLOXAMER GEL; DRUG-RELEASE; IN-VITRO; ABSORPTION; CHITOSAN; VIVO; MUCOADHESIVE; TRANSPORT;
D O I
10.1002/jps.22314
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
To enhance permeation and solubility of an intranasal delivery system of fexofenadine hydrochloride (FXD HCl), a new formulation using poloxamer 407 (P407)/hydroxypropyl-beta-cyclodextrin (HP-beta-CD)-based thermoreversible gels with chitosan, was developed. Prepared gels were characterized by gelation temperature, viscosity, viscoelasticity, and drug release profile. The in vitro permeation study was performed in primary human nasal epithelial cell monolayers cultured by air liquid interface method. The addition of chitosan caused the slight elevation of gelation temperature and viscosity-enhancing effect. Viscosity enhancement by the incorporation of chitosan caused the retardation of drug release from P407 gels in in vitro release test. The in vitro permeation profile showed that the increase in chitosan content (0.1% and 0.3%, w/v) significantly enhanced the permeation of FXD HCl. After intranasal administration of P407/HP-beta-CD-based thermoreversible gels containing 0.1% and 0.3% of chitosan in rabbits at 0.5 mg/kg dose, plasma concentrations of FXD HCl were significantly higher than those of nasal solutions (p < 0.05). In particular, the bioavailability of the optimized thermoreversible gel containing 0.3% chitosan was about 18-fold higher than that of the solution type. These results suggested the feasibility that thermosensitive gels could be used as an effective dosage form to enhance the nasal absorption of FXD HCl. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:681-691, 2011
引用
收藏
页码:681 / 691
页数:11
相关论文
共 41 条
[1]
Arima H, 2002, RRD CHE PHA, V2, P155
[2]
Permeability issues in nasal drug delivery [J].
Arora, P ;
Sharma, S ;
Garg, S .
DRUG DISCOVERY TODAY, 2002, 7 (18) :967-975
[3]
Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:: β-cyclodextrin complex [J].
Bilensoy, Erem ;
Rouf, M. Abdur ;
Vural, Imran ;
Sen, Murat ;
Hincal, A. Atilla .
AAPS PHARMSCITECH, 2006, 7 (02)
[4]
Effect of hydroxypropyl β-cyclodextrin on the self-assembling and thermogelation properties of Poloxamer 407 [J].
Bonacucina, Giulia ;
Spina, Michele ;
Misici-Falzi, Monica ;
Cespi, Marco ;
Pucciarelli, Stefania ;
Angeletti, Mauro ;
Palmieri, Giovanni F. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 32 (02) :115-122
[5]
Preparation and evaluation of a chitosan salt-poloxamer 407 based matrix for buccal drug delivery [J].
Cafaggi, S ;
Leardi, R ;
Parodi, B ;
Caviglioli, G ;
Russo, E ;
Bignardi, G .
JOURNAL OF CONTROLLED RELEASE, 2005, 102 (01) :159-169
[6]
Cyclodextrins in drug delivery: An updated review [J].
Challa, R ;
Ahuja, A ;
Ali, J ;
Khar, RK .
AAPS PHARMSCITECH, 2005, 6 (02)
[7]
Formulation and evaluation of ondansetron nasal delivery systems [J].
Cho, Eunsook ;
Gwak, Hyesun ;
Chun, Inkoo .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 349 (1-2) :101-107
[8]
Effect of additives on the physicochemical properties of liquid suppository bases [J].
Choi, HG ;
Lee, MK ;
Kim, MH ;
Kim, CK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 190 (01) :13-19
[9]
Synergistic gelation of xanthan gum with locust bean gum: a rheological investigation [J].
Copetti, G ;
Grassi, M ;
Lapasin, R ;
Pricl, S .
GLYCOCONJUGATE JOURNAL, 1997, 14 (08) :951-961
[10]
CORNAZ AL, 1994, EUR J PHARM BIOPHARM, V40, P261